Martin Everett


Martin has over 25 years’ experience in academia, pharmaceutical R&D (GSK) and biotechnology (MerLion, Antabio). At GSK he worked in anti-tubercular target development before managing an automated high-throughput screening group and leading several antibacterial and oncology lead discovery projects. At MerLion he was Head of Research leading a multi-disciplinary team discovering and developing novel natural product derived compounds and working on development of the fluoroquinolone antibiotic Finafloxacin. At Antabio, Martin is the CSO, leading the R&D team, and is PI for the PEI program funded by CARB-X.